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Introduction
Many European populations, including Poland, represent 
countries of high risk of cardiovascular diseases (CVD) 
(1). Recent studies of Polish population – NATPOL 2011 
showed that nearly 61% of adult Polish inhabitants (about 
18 million) have dyslipidemia (2), which is the main risk 
factor of CVD (3). The European Study on Cardiovascular 
Risk Prevention and Management in Usual Daily Practice 
showed that general prevalence of dyslipidaemia in Europe 
is about 57.7% of patients with at least one major risk factor 
for CVD (4) and ranges between 29% in Switzerland (5) till 
59.1% in Italy  (6) and 65.4% in Spain (7). Many genetic 
factors (including PPARγ2 or ADRβ3 genes) show variable 
association with dyslipidemia (8, 9) and can be modulated by 
selective nutrients intake (10, 11). Because polyunsaturated 
fatty acids and prostanoids (12) are the major natural ligands of 
the PPARγ2 gene, the quality of fat may affect transduction of 
metabolic signals (13). In animal studies an increase in PPARγ 
mRNA in adipose tissue was observed after a high-fat diet 
supplement (8). Moreover, C1431T polymorphism of PPARγ2 
gene is associated with metabolic disorders, dyslipidemia, and 
CVD development (14-16). Besides PPARγ2 gene, ADRβ3 
gene, located mainly in adipose tissue, also is involved in the 
regulation of lipolysis and thermogenesis (17); and the presence 
of Arg64 allele is related to the increased chances of gaining 
weight in Caucasians (25 year observation of obese subjects) 
(18). 
Some studies have reported on the combined role of genetic 
(e.g., Pro12Ala genotype) and lifestyle (such as dietary fatty 
acid ratio) factors in metabolic disorders (insulin resistance 
or BMI value) (10, 11). However, usually, in patients with 
metabolic disorders the already used medications could affect 
glucose and lipid concentrations or the expression of the 
PPARγ2 gene (e.g., thiazolidinediones and statins). Taking 
into consideration the above mentioned data, we attempted 
in our study to estimate the relationship between specific 
polymorphisms, nutritional status and dietary habits in a group 
of postmenopausal women, who were never diagnosed of 
or treated for dyslipidemia and show, which of the genetic 
factors may play an important role in the treatment strategies 
in this group. Moreover, we would like to indicate, which of 




In this study, 1,423 women, aged 49 to 75 years, were 
recruited and they underwent standard health checkups at 
a metabolic outpatient clinic. From this group, we 
selected postmenopausal women who did not undergo any 
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hypolipidemic or hypoglycemic treatment. After the 
gynecological interview (minimum 12 months of amenorrhea or 
bilateral oophorectomy), the hormonal assessment based on the 
measurement of follicle-stimulating hormone (FSH) confirmed 
the postmenopausal period. Women earlier diagnosed with 
or treated for dyslipidemia, severe cardiovascular diseases, 
endocrinological disorders, renal or liver dysfunction, cancer 
or the ones supplemented with minerals/vitamins/fitosterols 
were excluded from the study. Finally, we selected 271 
postmenopausal women, who undergo biochemical, nutritional, 
and genetic evaluation. The selection was random because 
PPARγ2 and ADRβ3 polymorphisms were unknown at 
the time of recruitment. The ethical approval was obtained 
from the respective local Bioethical Commission of Poznan 
Medical University, Poland, nr 792/09, and the guidelines 
proposed by the Declaration of Helsinki were followed. Written 
informed consent was obtained from all subjects before the 
commencement of the study.
Anthropometric measurements
Anthropometric measurements were directly taken in 
accordance with the International Standards for Anthropometric 
Assessment (19) by trained interviewers. Women’s weight, 
height, waist circumference, blood pressure, and bioimpedance 
were measured in the morning, using a standardized procedure. 
Body mass was determined in underwear in the standing upright 
position with electronic scales with a precision of 100 g (SECA 
scale). The height was determined to the nearest 0.1 cm. Waist 
circumference was measured at the midpoint between the 
lower margin of the least palpable rib and the top of the iliac 
crest, using a flexible measure to the nearest 0.1 cm. Body 
mass index was calculated as weight/height squared (kg/m2) 
and waist-to-hip ratio (WHR) as the proportion of waist-to-hip 
circumferences (20). A bioimpedance analyzer with a single 
frequency of 50 kHz (Bodystat 1500, Bodystat Ltd., United 
Kingdom) was used to assess the fat content to the proportion of 
total body mass. 
Biochemical evaluation
After 12 hour fasting, venous blood samples were collected 
from all patients at 7 A.M. Serum samples were taken from 
clotted (15 min, room temperature) and centrifuged blood (15 
min, 3 000 × g). Serum was separated and directly used for the 
assay. The obtained samples were used for the measurements 
of FSH levels and plasma lipid profile. The concentration of 
FSH was measured to confirm the postmenopausal age by 
chemiluminescence assays (Roche Diagnostics). The lipid 
profile was assessed with enzymatic colorimetric assays (Cobas 
Integra 400 Plus; Roche Diagnostics, Mannheim, Germany). 
Low density lipoprotein (LDL) cholesterol was calculated using 
Friedewald’s formula (21). 
According to the recommendation of European Society of 
Cardiology (ESC) and the European Atherosclerosis Society 
(EAS) the characteristic SCORE (Systematic Coronary Risk 
Estimation) was calculated for whole group of women (n=271). 
Estimated SCORE (based on data for no-smoking women aged 
60) was within the range of 1%–5%. The assessed coronary 
risk was moderate and thus LDL-cholesterol of 3 mmol/L 
(less than 115 mg/dL) should be considered as a target value 
in the analyzed group (2). The value of LDL <115 is also 
recommended by ESC as target in general population (without 
diagnosed CVD or diabetes mellitus, similar to the group in 
this study) (2, 22). Considering this evidence every subject with 
LDL level ≥115 mg was classified as dyslipidemic, while with 
LDL <115 mg/dL as normolipidemic. The lipid accumulation 
product (LAP) was calculated using the formula: LAP = (WC – 
58) × TG (nmol/L) (23, 24).  
Dietary evaluation
The food intake was assessed at a 24 hour interval for 7 
days and all women were on normal diet (traditional Polish 
diet). The estimated daily food rations (DFR) enabled the 
analysis of energy intake, basic nutritional components 
consumption (protein, fat and carbohydrates) and selected 
fatty acids intake (including SFA, MUFA, PUFA). The results 
of the questionnaire were analyzed with both the quantitative 
and qualitative analyzes of the subjects’ daily diets using 
computer databases for Microsoft Access 2000. The food 
intake recommendations of the National Institute of Food 
and Nutrition in Warsaw, Poland, were taken in to account 
to determine whether the Recommended Dietary Allowances 
(RDAs) specific for age, sex, ideal body mass, height, and 
physical activity were fulfilled (25). Dietary cholesterol was 
compared with the nutritional prophylaxis recommendations at 
the level of 200 mg (recommended in dyslipidemia) (20, 25). 
Genotyping
Genomic DNA was isolated from venous blood samples 
according to the manufacturer’s protocol (Gentra Puregene 
Blood Kit; QIAGEN, Venlo, Limburg). Genotypes of the 
Pro12Ala (rs1801282) and Trp64Arg polymorphism (rs4994) 
were determined by applying a TaqMan genotyping assay (Life 
Technologies, Carlsbad, CA). As a quality-control measure, 
negative controls and approximately 5% of samples were 
genotyped in duplicate to check genotyping accuracy. The 
controls for each of the genotypes of both single nucleotide 
polymorphisms were run in parallel. An allelic discrimination 
assay was performed on an ABI7900HT or on CFX96 Touch 
Real-Time PCR Detection System (Bio-Rad Laboratories, Inc, 
Hercules, CA). C1431T (rs3856806) genotyping was performed 
using PCR-restriction fragment length polymorphism (PCR-
RFLP) analysis. Eco72I cleaves the PCR product from wild-
type DNA to generate fragments of 127bp and 43bp, but does 
not cut products containing the variant allele. PCR-digests 
were analyzed on 2.5% agarose gels. The determination of 
the ADRβ3 variant was performed using the PCR method as 
described by Sivenius and colleagues (26). The genotypes were 
determined as Trp64Trp, Trp64Arg, and Arg64Arg without 
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earlier knowledge of the patients’ status.
Linkage disequilibrium block determination and haplotype 
construction
The genotype data were used to construct the haplotypes 
between the two polymorphisms by using Haploview 4.2 
software (Broad Institute, Cambridge, MA) to evaluate linkage 
disequilibrium (LD). Linkage disequilibrium between the single 
nucleotide polymorphisms used in haplotype analysis was 
measured using a pairwise D’ statistic. The structure of the LD 
block was examined with the method proposed by Gabriel and 
colleagues (27) using the 80% confidence bounds of D’. The 
haplotype frequencies were calculated based on the maximum 
likelihood method with Haploview 4.2 software. Finally, 
the associations between haplotypes and obesity status were 
checked. Specific haplotype frequencies were compared among 
lean and obese women (chi-square test). 
Statistical Analysis 
The Shapiro-Wilk test was used to determine if the 
continuous variables were normally distributed. Since the 
results were not consistent with normal distribution, 
nonparametric methods were used for the  statistical analysis. 
Continuous data were shown as mean ± standard deviation. 
The hypothesis that the differences between analyzed 
anthropometric and metabolic factors in the analyzed groups 
were significant was tested by Mann-Whitney U-test. As the 
number of Ala12Ala homozygotes were small (one lean woman 
and nine obese women), compared to Pro12Pro homozygotes, 
they were collapsed with Pro12Ala heterozygotes for all 
the analyzes. Similarly, C1431T heterozygotes and T1431T 
homozygotes were collapsed together, as well as Trp54Arg 
heterozygotes and Arg64Arg homozygotes. Allele frequencies 
were estimated using the gene-counting method, and an exact 
test was performed to identify departures from Hardy-Weinberg 
proportions (Court lab–HW calculator.xls). Genotype and allele 
frequencies according to normolipidemic (LDL <130 mg/
dL) and dyslipidemic state (LDL ≥130 mg/dL) were tested by 
Mann-Whitney U test. The association of analyzed genotypes 
with anthropometric and nutritional parameters in normo- and 
dyslipidemic women was also tested by Mann-Whitney U 
test. The odds ratio (OR) with a 95% confidence interval (CI) 
for gene polymorphisms according to normolipidemic (LDL 
<115 mg/dL) and hyperlipidemic state were determined. A 
P value <0.05 was regarded as statistically significant. The 
statistical analyzes were performed with STATISTICA 12 
(including STATISTICA Medical Package 2.0; StatSoft, Inc. 
2014 software) and SPSS 22 (IBM, Inc, Chicago, IL, USA).
Table 1
Anthropometric and nutritional characteristics  
of postmenopausal women





Age (years) 59.74±7.44 59.19±4.80 0.4984
Height (cm) 161.18±6.09 160.88±5.74 0.7223
Body mass (kg) 73.79±16.33 77.07±16.29 0.1761
Body fat (% body mass) 42.47±6.21 43.74±6.84 0.2072
BMI (kg/m2) 28.14±6.19 29.77±6.32 0.0827
WC (cm) 88.54±14.45 90.88±14.24 0.2701
WHR 0.83±0.08 0.83±0.07 0.5301
FSH 73.48±28.62 69.13±25.68 0.2659
TC (mg/dL) 184.74±9.21 243.44±36.00 0.00001
LDL (mg/dL) 99.62±12.57 155.31±31.76 0.00001
TG (mg/dL) 99.90±46.16 122.28±54.92 0.0048
HDL (mg/dL) 65.24±14.66 63.65±14.73 0.4675
LAP 37.06±30.68 48.83±34.31 0.0186
Energy (kcal) 1910.41±467.88 2087.39±575.16 0.0319
Protein (g) 77.95±18.74 81.04±21.34 0.3164
Fat (g) 71.62±18.98 80.59±26.62 0.0170
Carbohydrates [g) 242.99±78.18 263.52±81.39 0.0871
SFA-%energy 11.43±2.14 12.29±2.47 0.0164
MUFA-%energy 13.13±2.66 13.21±2.82 0.8435
PUFA-%energy 6.08±1.75 5.58±1.74 0.0503
PUFA/SFA ratio 0.61±0.26 0.54±0.23 0.0332
Dietary cholesterol (mg) 399.25±138.83 453.89±201.70 0.0534
Butyric acid C4:0 (g) 0.65±0.27 0.80±0.39 0.0065
Caproic acid C6:0 (g) 0.40±0.17 0.50±0.24 0.0053
Caprylic acid C8:0 (g) 0.25±0.10 0.30±0.14 0.0043
Capric acid C10:0 (g) 0.60±0.24 0.73±0.34 0.0064
Lauric acid C12:0 (g) 0.82±0.34 0.98±0.44 0.0139
Myristic acid C14:0 (g) 2.73±1.02 3.33±1.39 0.0024
Pentadecylic acid C15:0 (g) 0.29±0.11 0.36±0.15 0.0007
Palmitic acid C16:0 (g) 12.43±3.47 14.47±5.08 0.0043
Margaric acid C17:0 (g) 0.25±0.09 0.31±0.13 0.0013
Stearic acid C18:0 (g) 5.58±1.76 6.59±2.61 0.0059
Tetradecenoic acid C14:1 (g) 0.34±0.14 0.41±0.17 0.0066
Ginkgolic acid C15:1 (g) 0.14±0.05 0.18±0.08 0.0012
Palmitoleic acid C16-1 (g) 1.56±0.53 1.84±0.69 0.0046
Heptadecenoic acid C17-1 (g) 0.24±0.10 0.30±0.14 0.0027
Vaccenic acid C18:1 (g) 24.23±7.23 27.20±10.52 0.0444
No significant differences between analyzed groups and the intake of arachidic acid 
C20:0, paullinic acid C20:1, erucic acid C22:1, linoleic acid C18:2, α-Linolenic acid 
C18:3-alfa, stearidonic acid C18:4, dihomo-γ-linolenic acid C20:3, arachidonic acid 
C20:4, eicosapentaenoic acid C20:5, docosapentaenoic acid C22:5, and docosahexaenoic 
acid C22:6; BMI–body mass index; WC–waist circumference; WHR–waist to hip ratio; 
FSH–follicle-stimulating hormone; TC–total cholesterol; LDL–low density lipoproteins; 
TG–triglycerides; HDL–high density lipoprotein; LAP–lipid accumulation product; 
SFA–saturated fatty acids, MUFA–monounsaturated fatty acids, PUFA–polyunsaturated 
fatty acids.
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Table 2
Genotype and allele frequencies of the Pro12Ala and 
C1431/X PPARγ2 and Trp 64Arg of β-adrenergic receptor 
gene polymorphisms according to normolipidemic (LDL 
<130 mg/dL) and dyslipidemic state (LDL ≥130 mg/dL). 








Pro12Pro 39 (67.24%) 145 (68.08%) 184 (67.90%)
Pro12Ala 16 (27.59%) 61 (28.64%) 77 (28.41%)
Ala12Ala 3 (5.17%) 7 (3.28%) 10 (3.69%)
Chi-square value (P value) 0.7938 (ns)
Allele frequency
Pro 94 (0.810) 351 (0.824) 445 (0.821)
Ala 22 (0.190) 75 (0.176) 97 (0.179)
Chi-square value (P value) OR= 1.095
OR (95% CI) 95% CI: 0.6466–1.855
Genotype
C1431C 41 (70.69%) 157 (73.71%) 198 (73.06%)
C1431T 13 (22.41%) 52 (24.41%) 65 (23.99%)
T1431T 4 (6.90%) 4 (1.88%) 8 (2.95%)
Chi-square value (P value) 0.8475 (ns)*
Allele frequency
C1431 95 (0.819) 366 (0.859) 461 (0.851)
T1431 21 (0.181) 60 (0.141) 81 (0.149)
Chi-square value (P value) OR = 1.348
OR (95% CI) 95% CI: 0.7812–2.328
Genotype
Trp64Trp 47 (81.03%) 172 (80.75%) 219 (80.81%)
Trp64Arg 11 (18.97%) 37 (17.37%) 48 (17.71%)
Arg64Arg 0 (0.00%) 4 (1.88%) 4 (1.48%)
Chi-square value (P value) 0.8475 (ns)**
Allele frequency
Trp 105 (0.905) 381 (0.894) 486 (0.897)
Arg 11 (0.095) 45 (0.106) 56 (0.103)
Chi-square value (P value) OR =0.8870
OR (95% CI) 95% CI: 0.4432–1.775
* C1431C and C1431T that counts for T1431T are too small for testing the 3×2 
contingency table; ** Trp64Trp and Trp64Arg that counts for Arg64Arg are too small 
for testing the 3×2 contingency table
Results
The anthropometric parameters of dyslipidemic and 
normolipidemic subjects were comparable in both groups 
(Table 1). All women were overweight (BMI >25 kg/m2) and 
characterized with visceral distribution of fat (WC >80 cm) 
(28). Besides differences in LDL level (used as independent 
variable to classify the patients as normolipidemic or 
dyslipidemic) we also observed the differences in TC, TG, 
and non-HDL cholesterol between analyzed groups. The 
lipid accumulation product (LAP) was significantly higher in 
dyslipidemic group. The intake of energy as total fat and as 
saturated fatty acids (SFA) expressed in percent of total energy 
intake and analyzed individually (as butyric, caproic, caprylic, 
capric, lauric, myristic, pentadecylic, palmitic, margaric, and 
stearic acid, C4:0 – C20:0) and as monounsaturated fatty acids 
(such as tetradecanoic, ginkgolic, palmitoleic, heptadecanoic, 
and vaccenic acid, C14:1 – C18:1) were higher in dyslipidemic 
women. There were no statistically significant differences 
between the intake of total amount of PUFA (expressed as 
percent of energy intake) and selected PUFA in analyzed 
group (linoleic, α-Linolenic, stearidonic, dihomo-γ-linolenic, 
arachidonic, eicosapentaenoic, docosapentaenoic, and 
docosahexaenoic acid). The dietary cholesterol intake was 
higher in dyslipidemic group, while the ratio of PUFA to SFA 
was lower. 
The analysis of confidence intervals and odds ratios showed 
no statistically significant differences between analyzed allele 
frequencies in normolipidemic and dyslipidemic women (Table 
2). The data present in Table 3 has revealed not only the 
nutritional influence on LDL level, but also various gene–diet 
relations with dyslipidemia. Within the same polymorphism 
(Table 3, Part A), higher intake of energy, SFA, and C15:0 and 
lower intake of PUFA determined the higher level of LDL. 
Normolipidemic women with Ala12/X polymorphism (Table 3, 
Part B) were characterized by their higher waist circumference 
and higher PUFA intake. The diet of dyslipidemic subjects with 
Arg64/X polymorphism (Table 3, Part C) contained higher 
energy from nutrients, fat, and arachidic acid intake.
Discussion
Several factors were proposed to be associated with 
dyslipidemia including dietary habits, physical activity, and 
genetic background (9, 29-32). However, the studies describing 
such relations in postmenopausal age are very scarce (33, 34), 
and to our knowledge neither of them describe the diet–gene 
interaction in newly diagnosed postmenopausal dyslipidemia. 
In this study, we found both nutritional and genetic associations 
with the dyslipidemic state. 
The analyzed groups of women (Table 1) were overweight 
(BMI ≥25<30 kg/m2) (20, 28). The waist circumference 
(WC) and WHR ratio over-crossed recommended values in 
normolipidemic and dyslipidemic subjects (WC >80 cm and 
WHR >0.8) (28). These parameters show the central deposition 
of fat, which is considered not only as a risk factor of CVD 
diseases in postmenopausal age (35), but also as a risk factor of 
breast cancer (36). Beside this, LAP (a novel index of central 
lipid accumulation) was found to be elevated in both groups and 
was significantly higher in dyslipidemic women. In European 
population, the optimal cut-off value of LAP for the screening 
of metabolic syndrome is 33.28 in females (37). Increased LAP 
in both groups shows not only a central lipid accumulation, but 
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also predicts the risk of metabolic syndrome (23, 38) and CVD 
development (23, 37).
The intake of energy, as fat and saturated fatty acids 
were higher in dyslipidemic women, while PUFA/SFA ratio 
was lower (Table 1). Mainly the excess of SFA causes an 
elevated LDL level and the substitution of these acids for 
polyunsaturated fat in the diet results in the decrease of both 
total cholesterol and LDL concentration (39, 40). Beside the 
excess of SFA, low amount of PUFA were noted in both 
groups, what influences on high LDL level (41, 42). The proper 
amount of saturated acids range from 8%–9% of energy in 
DFR, MUFA 13%–14%, and PUFA at 8%–9% (Mediterranean 
diet) (37). MUFA were within the recommended range 
and may cause quite high HDL (“protective”) level in both 
normolipidemic and dyslipidemic group (37, 43, 44).
In this study, we did not confirm the differences between 
Table 3
The association of analyzed genotypes with anthropometric and nutritional parameters in normo- and dyslipidemic women
Polymorphism LDL level Analyzed parameters X ± SD n P value
A. Different LDL level
Ala12/X Dyslipidemic Energy (kcal) 2168.91±573.83 68 0.0217
Normolipidemic 1829.93± 463.14 18
Dyslipidemic C15:0 (g) 0.37±0.15 68 0.0208
Normolipidemic 0.28±0.11 18
Dyslipidemic PUFA-%energy 5.29±1.71 68 0.0208
Normolipidemic 6.24±1.43 18
Pro12Pro Dyslipidemic SFA-%energy 12.42±2.44 147 0.0259
Normolipidemic 11.44±2.35 38
Dyslipidemic C15-0 (g) 0.35±0.14 147 0.0186
Normolipidemic 0.29±0.11 38
C1431C Dyslipidemic Fat (g) 81.75±26.68 158 0.0144
Normolipidemic 70.75±18.72 40
Dyslipidemic C20:0 (g) 0.29±0.14 158 0.0111
Normolipidemic 0.25±0.08 40
T1431/X Dyslipidemic Saccharose-%energy 9.32±3.52 57 0.0377
Normolipidemic 8.43±3.28 16
Dyslipidemic Fat-% energy 33.42±4.77 57 0.0187
Normolipidemic 34.62±4.64 16
Arg64/X Dyslipidemic C20:0 (g) 0.28±0.11 41 0.0494
Normolipidemic 0.29±0.08 10
B. Different polymorphisms
Pro12Pro Normolipidemic Waist circumference 86.16±13.38 38 0.0465
Ala12/X 94.31±15.81 18
Pro12Pro PUFA-% energy 6.017±1.92 38 0.04028
Ala12/X 6.24±1.43 18
C. Different polymorphisms and LDL level
Trp64Trp Normolipidemic Energy (kcal)
1923.69± 500.42 46 0.0414
Arg64/X Dyslipidemic 2168.09± 587.84 41
Trp64Trp Normolipidemic Fat (g) 71.93±19.98 46 0.0110
Arg64/X Dyslipidemic 85.79±26.09 41
Trp64Trp Normolipidemic C20:0 (g) 0.28±0.12 46 0.0081
Arg64/X Dyslipidemic 0.28±0.11 41
C15:0–pentadecylic acid; C20:0–arachidic acid; SFA– saturated fatty acids; PUFA– polyunsaturated fatty acids
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gene distribution and the presence of dyslipidemia (Table 2). 
However, we have observed some associations of nutritional 
and genetic background with the level of LDL. We have 
showed that Ala12 genotype may be related to the lower risk 
of dyslipidemia (Table 3, Part B) and this genotype together 
with the dietary factors (higher intake of PUFA) seems to play 
a protective role. Because, even though Ala carriers had higher 
waist circumference, they remained normolipidemic. Similar 
to our study, Robitaille at al., have showed that each 10 g 
increment in fat intake was associated with an increase of 1.2 
cm in waist circumference among Pro12/Pro12 homozygotes, 
whereas no significant change in WC was observed among 
carriers of the Ala12 allele (11). The normolipidemic state in 
Ala12/X polymorphism can also be partially explained by the 
fact of higher intake of PUFA, which have beneficial influence 
on the lipid profile and decrease the risk of CVD development 
(30-33). 
Dyslipidemic women with Arg64/X polymorphism of the 
ADRβ3 were characterized with higher intake of energy, total 
fat, and arachidic acid (C20:0). Thus, this polymorphism seems 
to be related to dyslipidemic state and can increase the lipid 
disorders if it is associated by higher intake of proatherogenic 
nutrients. This evidence is confirmed by the study of Asian 
(45) and Caucasian populations (18), which have shown that 
Arg64 allele is associated with obesity development. Moreover, 
obese subjects with this allele are predisposed to lipid disorders 
(higher TC, LDL, and TG) (46). Therefore, the association of 
the Arg64 allele with an inadequate amount and quality of fat 
in daily food rations of the analyzed women can be predisposed 
to postmenopausal dyslipidemia. We conclude that both genetic 
background and nutritional habits are related to health status in 
an aging population (18, 45, 46,47).
Conclusion
To our knowledge this is the first study, which showed 
a genetic associations of ADRβ3 and PPARγ2 variants 
and eating behavior in postmenopausal women with 
dyslipidemia who did not undergo hypolipidemic treatment. 
The dyslipidemia was first time diagnosed in nearly 80% of 
postmenopausal women, which suggest the need for early 
diagnosis, dietary modification, and/or hypolipidemic treatment 
in postmenopausal women to prevent CVD development. 
According to the recommendations of ESC and the European 
Atherosclerosis Society (EAS) women with LDL ≥115 mg/
dL should undertake lifestyle interventions including dietary 
modification and increased physical activity. Therefore, lower 
intake of fat and SFA and higher intake of PUFA should 
be recommended. Alongside, the presented results suggest 
that some polymorphisms together with the selected nutrients 
are related to dyslipidemia. Therefore, Ala12 (protective) 
and Arg64 allele (predisposing to dyslipidemia) may play an 
important role in the treatment strategies in long-term weight 
changes in viscerally overweight postmenopausal women with 
newly diagnosed dyslipidemia.  
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